文献速递主动脉疾病

腹主动脉与胸主动脉腔内修复术中内皮锚定装置的有效性与安全性:系统评价与荟萃分析

Effectiveness and Safety of Endoanchors in Abdominal and Thoracic Endovascular Aneurysm Repair: A Systematic Review and Meta-analysis.
PubMed 文献 · J Endovasc Ther · 2024-04-16

本系统评价与荟萃分析检索至2023年5月31日的4个数据库,纳入16项EVAR研究(n=1145)和6项TEVAR研究(n=163),评估Heli-Fx EndoAnchor系统的有效性与安全性。结果显示EVAR和TEVAR中内漏、支架移位和再干预率均较低,EVAR死亡率极低但TEVAR较高;作者认为长期疗效与安全性数据及随机对照试验是明确推荐常规临床使用的必要条件。

要点

  • EVAR患者平均随访11.9个月,内漏率3.97%、支架移位率0.004%、再干预率5.43%。
  • TEVAR患者内漏率7.4%、支架移位率0.2%、再干预率17.1%,30天死亡率0.9%。
  • 作者认为长期疗效与安全性数据及随机对照试验是明确推荐常规临床使用的必要条件。

核心结论

  • 内皮锚定装置固定用于EVAR和TEVAR在预防和治疗内漏及支架移位方面有效且安全。
  • EVAR中死亡率极低,但TEVAR中较高。
  • 作者认为长期疗效与安全性数据及随机对照试验是明确推荐内皮锚定装置用于常规临床实践的必要条件。

研究设计与样本

  • 按PRISMA指南开展的系统评价与荟萃分析。
  • 检索截至2023年5月31日的文献,从4个数据库独立筛选。
  • 纳入16项EVAR研究(n=1145)和6项TEVAR研究(n=163),均使用Heli-Fx EndoAnchor系统,源自2225条检索记录。
  • 数据合并进行荟萃分析。

主要发现

  • EVAR患者(平均随访11.9个月)内漏率3.97%(95%CI=0.36%-1.99%)、支架移位率0.004%(95%CI=0.00%-0.76%)、再干预率5.43%(95%CI=0.86%-12.54%)。
  • 原发性EVAR内漏率0.16%(95%CI=0.00%-1.65%),翻修性EVAR内漏率3.60%(95%CI=0.14%-9.72%)。
  • 文献中仅报告4例30天死亡率(n=4)。
  • TEVAR患者内漏率7.4%(95%CI=0.03%-0.13%)、支架移位率0.2%(95%CI=0.00%-0.06%)、再干预率17.1%(95%CI=0.01%-0.45%),30天死亡率0.9%(95%CI=0%-0.12%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为需要长期疗效与安全性数据及随机对照试验才能明确推荐内皮锚定装置用于常规临床实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This systematic review aimed to summarize the effectiveness and safety of endoanchor, a stabilizing device for the proximal endograft designed to prevent endoleak and stent migration in endovascular aneurysm repair (EVAR) and thoracic endovascular aneurysm repair (TEVAR). MATERIALS AND METHODS: A systematic review and meta-analysis was conducted per the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guideline. Literature up to May 31, 2023 was searched and independently screened from 4 databases. Data were pooled for meta-analysis. Primary outcomes included intraoperative and follow-up endoleak, stent migration, and reintervention rates; sac regression; and 30-day all-cause mortality. RESULTS: Sixteen EVAR (n=1145) and 6 TEVAR studies (n=163) using the Heli-Fx EndoAnchor system were included from 2225 retrieved records. For EVAR patients (mean follow-up=11.9 months), the endoleak, graft migration, and reintervention rates were 3.97% (95% confidence interval [CI]=0.36%-1.99%), 0.004% (95% CI=0.00%-0.76%), and 5.43% (95% CI=0.86%-12.54%), respectively. The endoleak rates for primary and revision EVAR were 0.16% (95% CI=0.00%-1.65%) and 3.60% (95% CI=0.14%-9.72%), respectively. Only 4 cases of 30-day mortality (n=4) were reported in the literature. For TEVAR patients, the endoleak, stent migration, and reintervention rates were 7.4% (95% CI=0.03%-0.13%), 0.2% (95% CI=0.00%-0.06%), and 17.1% (95% CI=0.01%-0.45%), respectively. The 30-day mortality was 0.9% (95% CI=0%-0.12%). CONCLUSIONS: Endoanchor fixation in EVAR and TEVAR is effective and safe in preventing and treating endoleak and stent migration. The mortality is minimal in EVAR but higher in TEVAR.Clinical ImpactEndoleak, graft migration, and reintervention in EVAR and TEVAR with endoanchor use were rare. Mortality in EVAR was low. The adjunctive deployment of endoanchors is an effective and safe means to prevent and treat endoleak and stent migration in EVAR and TEVAR. Yet, long-term efficacy and safety data and randomized controlled trials would be required to definitively recommend endoanchor use in routine clinical practice.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Tang EWC, Lau ACK, Cheng JCH, et al. Effectiveness and Safety of Endoanchors in Abdominal and Thoracic Endovascular Aneurysm Repair: A Systematic Review and Meta-analysis. J Endovasc Ther. 2024. PMID: 38628025. doi:10.1177/15266028241245911

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。